PDCD1 and breast cancer: Consequently, TNBC is the target of most current BC immunotherapy trials with anti-PD-1 and anti-PD-L1 agents demonstrating the best clinical benefits (although limited to a subset of patients) when given in the advanced and neoadjuvant settings (18).